These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8507135)

  • 1. [Adverse effects of oxybutynin chloride (Ditropan) in pediatrics].
    Jonville AP; Dutertre JP; Barbellion M; Autret E
    Arch Fr Pediatr; 1993 Jan; 50(1):27-9. PubMed ID: 8507135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse effects of oxybutynin chloride (Ditropan). Evaluation of the official survey of Regional Pharmacovigilance Centers].
    Jonville AP; Dutertre JP; Autret E; Barbellion M
    Therapie; 1992; 47(5):389-92. PubMed ID: 1299977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
    Van Arendonk KJ; Knudson MJ; Austin JC; Cooper CS
    Urology; 2006 Oct; 68(4):862-5. PubMed ID: 17070368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
    Maillard H; Fenot M; Bara C; Célérier P
    Ann Dermatol Venereol; 2011 Oct; 138(10):652-6. PubMed ID: 21978500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.
    Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD
    J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.
    Wolosker N; Schvartsman C; Krutman M; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
    Pediatr Dermatol; 2014; 31(1):48-53. PubMed ID: 23627681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Instability of the detrusor. Treatment with oxybutynin chloride (Ditropan) in children].
    Vallejo Herrador J; Rodríguez Luna JM; Fernández Fernández A; Perales Cabanas L; Romero Maroto J; Pérez Bustamante I
    Actas Urol Esp; 1990; 14(1):23-7. PubMed ID: 2339646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin efficacy in the treatment of primary enuresis.
    Lovering JS; Tallett SE; McKendry JB
    Pediatrics; 1988 Jul; 82(1):104-6. PubMed ID: 3288951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose oxybutynin for the unstable bladder.
    Malone-Lee J; Lubel D; Szonyi G
    BMJ; 1992 Apr; 304(6833):1053. PubMed ID: 1586797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.